Detalhe da pesquisa
1.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 23(2): 279-291, 2022 02.
Artigo
Inglês
| MEDLINE | ID: mdl-35033226